Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 93-97

  Montes, Milagrosa ^a,b   Tamayo, Esther ^a   Orden, Beatriz ^c   Larruskain, Julián ^b   Perez Trallero, Emilio ^a,b,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CIPROFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CLINICAL ARTICLE; GENE CLUSTER; GENE MUTATION; GENETIC TRAIT; GROUP A STREPTOCOCCAL INFECTION; HUMAN; ISOLATION PROCEDURE; MAXIMUM ALLOWABLE CONCENTRATION; MEFA GENE; MOLECULAR CLONING; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PREVALENCE; PRIORITY JOURNAL; SPAIN; STREPTOCOCCUS PYOGENES;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PROSPECTIVE STUDIES; SPAIN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 73849104909     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00780-09     Document Type: Article

References (28)

1. Alberti, S., G. Cortes, C. Garcia-Rey, C. Rubio, F. Baquero, J. A. Garcia-Rodriguez, E. Bouza, and L. Aguilar. 2005. Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity. Antimicrob. Agents Chemother. 49:418-420.
2. Alonso, R., E. Mateo, G. Ezpeleta, and R. Cisterna. 2007. Characterisation of levofloxacin-resistant clinical isolates of Streptococcus pyogenes in Bilbao, Spain. Int. J. Antimicrob. Agents 30:183-185.
3. Alonso, R., E. Mateo, M. Galimand, J. Garaizar, P. Courvalin, and R. Cisterna. 2005. Clonal spread of pediatric isolates of ciprofloxacin- resistant, emm type 6 Streptococcus pyogenes. J. Clin. Microbiol. 43:2492-2493.
4. Alos, J. I., B. Aracil, J. Oteo, and J. L. Gomez-Garces. 2003. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. J. Antimicrob. Chemother. 51:333-337.
5. Barberan, J., L. Aguilar, M. J. Gimenez, G. Carroquino, J. J. Granizo, and J. Prieto. 2008. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int. J. Antimicrob. Agents 32:154-157.
6. Bessen, D. E. 2009. Population biology of the human restricted pathogen, Streptococcus pyogenes. Infect. Genet. Evol. 9:581-593.
7. Carapetis, J. R. 2004. Current issues in managing group A streptococcal infections. Adv. Exp. Med. Biol. 549:185-190.
8. Carapetis, J. R., A. C. Steer, E. K. Mulholland, and M. Weber. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694.
9. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
10. de la Campa, A. G., C. Ardanuy, L. Balsalobre, E. Pérez- Trallero, J. M. Marimón, A. Fenoll, and J. Liñares. 2009. Changes in fluoroquinoloneresistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911.
11. Ikebe, T., K. Hirasawa, R. Suzuki, J. Isobe, D. Tanaka, C. Katsukawa, R. Kawahara, M. Tomita, K. Ogata, M. Endoh, R. Okuno, and H. Watanabe. 2005. Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections. Antimicrob. Agents Chemother. 49:788-790.
12. Malhotra-Kumar, S., C. Lammens, S. Chapelle, C. Mallentjer, J. Weyler, and H. Goossens. 2005. Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J. Antimicrob. Chemother. 55:320-325.
13. Malhotra-Kumar, S., L. Van Heirstraeten, C. Lammens, S. Chapelle, and H. Goossens. 2009. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J. Antimicrob. Chemother. 63:886-894.
14. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27-S72.
15. Orscheln, R. C., D. R. Johnson, S. M. Olson, R. M. Presti, J. M. Martin, E. L. Kaplan, and G. A. Storch. 2005. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J. Infect. Dis. 191:1272-1279.
16. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
17. Pérez-Trallero, E., C. Fernandez-Mazarrasa, C. Garcia-Rey, E. Bouza, L. Aguilar, J. Garcia-de-Lomas, and F. Baquero. 2001. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob. Agents Chemother. 45:3334-3340.
18. Pérez-Trallero, E., C. Garcia, B. Orden, J. M. Marimon, and M. Montes. 2004. Dissemination of emm28 erythromycin-, clindamycin- and bacitracinresistant Streptococcus pyogenes in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 23:123-126.
19. Pérez-Trallero, E., J. M. Marimon, M. Montes, B. Orden, and M. de Pablos. 1999. Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain. Emerg. Infect. Dis. 5:235-240.
20. B phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob. Agents Chemother. 51:1228-1233.
21. Reinert, R. R., R. Lutticken, and A. Al-Lahham. 2004. High-level fluoroquinolone resistance in a clinical Streptococcus pyogenes isolate in Germany. Clin. Microbiol. Infect. 10:659-662.
22. Richter, S. S., D. J. Diekema, K. P. Heilmann, L. S. Almer, V. D. Shortridge, R. Zeitler, R. K. Flamm, and G. V. Doern. 2003. Fluoroquinolone resistance in Streptococcus pyogenes. Clin. Infect. Dis. 36:380-383.
23. Rivera, A., M. Rebollo, F. Sanchez, F. Navarro, E. Miro, B. Mirelis, and P. Coll. 2005. Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain. Clin. Microbiol. Infect. 11:759-761.
24. Seal, D. V. 2001. Necrotizing fasciitis. Curr. Opin. Infect. Dis. 14:127-132.
25. Silva-Costa, C., M. Ramirez, and J. Melo-Cristino. 2006. Identification of macrolide-resistant clones of Streptococcus pyogenes in Portugal. Clin. Microbiol. Infect. 12:513-518.
26. Yan, S. S., M. L. Fox, S. M. Holland, F. Stock, V. J. Gill, and D. P. Fedorko. 2000. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob. Agents Chemother. 44: 3196-3198.
27. Yan, S. S., P. C. Schreckenberger, X. Zheng, N. A. Nelson, S. M. Harrington, J. Tjhio, and D. P. Fedorko. 2008. An intrinsic pattern of reduced susceptibility to fluoroquinolones in pediatric isolates of Streptococcus pyogenes. Diagn. Microbiol. Infect. Dis. 62:205-209.
28. Zhanel, G. G., D. J. Hoban, K. Schurek, and J. A. Karlowsky. 2004. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 24:529-535.